AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Integrating MRD Testing in AML Management
This chapter examines the role of minimal residual disease (MRD) testing in the treatment of acute myeloid leukemia (AML) for patients with favorable risk cytogenetics. It discusses how MRD status can guide critical treatment decisions, potentially reducing unnecessary allogeneic transplants while ensuring positive survival rates.